See more : Blue Pearl Texspin Limited (BPTEX.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Soleno Therapeutics, Inc. (SLNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soleno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Arman Holdings Limited (ARMAN.BO) Income Statement Analysis – Financial Results
- Four Nines Gold Inc. (FNAUF) Income Statement Analysis – Financial Results
- Saudi Industrial Services Company (2190.SR) Income Statement Analysis – Financial Results
- Morabaha Marina Financing Company (4082.SR) Income Statement Analysis – Financial Results
- TIL Limited (TIL.BO) Income Statement Analysis – Financial Results
Soleno Therapeutics, Inc. (SLNO)
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55B | 1.45M | 387.56K | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 1.51M | 352.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.96M | -2.21M | -2.21M | -2.19M | -2.30M | -1.92M | -1.55B | -58.52K | 34.87K | 0.00 | 3.00M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.10% | -4.03% | 9.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| General & Administrative | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.58M | 6.74M | 6.14M | 2.67M | 1.47M | 1.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.73K | 1.63M | 1.74M | 252.36K | 0.00 | 0.00 |
| SG&A | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Other Expenses | 2.71M | 0.00 | 0.00 | 4.34M | 289.00K | 6.00K | -585.95K | -100.52K | -183.57K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.60M |
| Cost & Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.60M |
| Interest Income | 2.58M | 300.00K | 110.00K | 13.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 1.77K | 3.10K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 0.00 | 4.13M | 2.86M | 2.87M |
| Depreciation & Amortization | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 19.70K | 108.23K | 28.52K | 42.11K | 43.79K |
| EBITDA | -37.03M | -21.86M | -28.70M | -30.00M | -28.48M | -9.92M | -8.07M | -6.72M | -15.80M | -5.13M | -804.86K | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | -1,043.96% | -3,943.82% | 0.00% | -26.83% | 0.00% |
| Operating Income | -41.38M | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.78% | -938.12% | -3,137.55% | 0.00% | -28.23% | 0.00% |
| Total Other Income/Expenses | 2.40M | 330.00K | 618.00K | 11.65M | -7.29M | 2.46M | -1.27M | 1.59M | -3.75M | -8.08M | -2.86M | -2.88M |
| Income Before Tax | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.88% | -830.14% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| Income Tax Expense | 0.00 | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.70K | -183.57K | -455.08K | 2.86M | 2.84M |
| Net Income | -38.99M | -20.32M | -29.56M | -15.38M | -35.92M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% | -831.63% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| EPS | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| Weighted Avg Shares Out | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Weighted Avg Shares Out (Dil) | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
Why Is Soleno Therapeutics (SLNO) Stock Up 420% Today?
Soleno Therapeutics (NASDAQ: SLNO ) stock is rocketing higher on Tuesday after the biopharmaceutical company announced positive clinical trial data. The big news here is the company seeing statistically significant results from its long-term treatment study of DCCR.
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022)
Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at...
Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the second...
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?
Though clinical-stage biopharmaceutical firm Soleno Therapeutics (NASDAQ: SLNO ) encountered more than its fair share of setbacks this year, it blitzed rival enterprises on Monday. Earlier this morning, management disclosed a securities purchase agreement with Nantahala Capital Management, Abingworth and...
Penny Stocks To Buy Now? 6 To Watch With Big News Today
Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?
4 Small Stocks to Bet on in an Upbeat Drugs Industry
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
Good Penny Stocks to Buy Right Now? 3 to Watch Tomorrow
Can these penny stocks make gains tomorrow? The post Good Penny Stocks to Buy Right Now?
Source: https://incomestatements.info
Category: Stock Reports